ALACRITA
LIVE

Serial Number

85557129

Owner

Alacrita LLP

Attorney

Jeff Goehring

Filing Date

Mar 1, 2012

Add to watchlist:

No watchlists yet
View on USPTO

ALACRITA Trademark

Serial Number: 85557129 • Registration: 4256669

ALACRITA is a trademark filed by Alacrita LLP on March 1, 2012. The trademark is classified under Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Alacrita LLP

2, Royal College Street
London NW10NH , GB

Entity Type: 21

Alacrita Holdings Limited (3 trademarks)

London Bioscience Innovation Centre
London NW10NH , GB

Entity Type: 99

Trademark Details

Filing Date

March 1, 2012

Registration Date

December 11, 2012

Published for Opposition

September 25, 2012

Goods & Services

Financial advice for companies in the fields of pharmaceuticals, biotechnology, life sciences, medical products, medical devices and healthcare industries; arranging funding, namely, providing financing services, investment consultancy; information, consultancy and advice relating to any of the aforesaid services

Business and market research; business analysis, business planning, business management and business strategy, namely, strategic planning services, strategy development services and business consultancy in the fields of pharmaceuticals, biotechnology, life sciences, medical products, medical devices and healthcare industries; business advice regarding the development and commercialization of products in the fields of pharmaceuticals, biotechnology, life sciences, medical products, medical devices and healthcare industries; recruitment and personnel services, namely, personnel placement; tax services, namely, tax consultation and accountancy services; advertising and promotional services; arranging business networking meeting opportunities for businesses to meet potential investors and to promote their products; information, consultancy and advice relating to any of the aforesaid services; management of clinical trials for drugs, vaccines, diagnostic reagents, small molecules, medical devices, namely, providing information management services, providing clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and application for drug approval, or providing independent reviews of clinical trials for business purposes; preparation of reports on clinical trials of drugs, vaccines, diagnostic reagents, small molecules, and medical devices, namely, providing information, management and compilation of computerized databases in the field of clinical trials for business purposes; preparing technical business or financial reports on clinical trials of drugs, vaccines, diagnostic reagents, small molecules, medical devices, preparation of reports on clinical trials of drugs, vaccines, diagnostic reagents, small molecules, and medical devices

Research in the field of pharmaceuticals, biotechnology, life sciences, medical products, medical devices and scientific research in the field of healthcare industries; clinical research, namely, managing clinical trials for others, providing medical and scientific research information in the field of clinical trials; testing of pharmaceuticals, diagnostic reagents or medical products; conducting of clinical trials for others for drugs, vaccines, diagnostic reagents, small molecules, medical devices; providing scientific information, namely, preparation of reports on clinical trials of drugs, vaccines, diagnostics, small molecules, cellular therapies, medical devices, and research reagents; scientific research, namely, writing of medical research and scientific research-related documents and preparing reports on medical research and scientific research-related documents; testing the safety of pharmaceuticals, vaccines, diagnostic reagents, small molecules, cellular therapies, and medical devices, and information, consultancy and advice relating to any of the aforesaid services; consultancy, advice and information in the field of development of drugs, vaccines, diagnostic reagents, small molecules, and medical devices

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Jul 1, 2023 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Jun 30, 2023 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Jun 30, 2023 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 30, 2023 APRE
TEAS SECTION 8 & 9 RECEIVED
Dec 6, 2022 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Dec 11, 2021 REM2
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 15, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 15, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Nov 15, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 15, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 15, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 15, 2020 COAR
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Dec 8, 2018 NAS8
REGISTERED - SEC. 8 (6-YR) ACCEPTED
Dec 8, 2018 8.OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 8, 2018 APRE
TEAS SECTION 8 RECEIVED
Dec 3, 2018 ES8R
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 11, 2017 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 24, 2017 ASGN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 19, 2014 TCCA
REGISTERED-PRINCIPAL REGISTER
Dec 11, 2012 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 25, 2012 NPUB
PUBLISHED FOR OPPOSITION
Sep 25, 2012 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 5, 2012 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 22, 2012 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 22, 2012 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 22, 2012 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 22, 2012 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 22, 2012 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 22, 2012 CNEA
AMENDMENT FROM APPLICANT ENTERED
Aug 16, 2012 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 16, 2012 CRFA
FAX RECEIVED
Aug 14, 2012 FAXX
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 31, 2012 GNFN
FINAL REFUSAL E-MAILED
Jul 31, 2012 GNFR
FINAL REFUSAL WRITTEN
Jul 31, 2012 CNFR
AMENDMENT FROM APPLICANT ENTERED
Jul 12, 2012 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 12, 2012 CRFA
ASSIGNED TO LIE
Jul 12, 2012 ALIE
FAX RECEIVED
Jul 2, 2012 FAXX
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 19, 2012 GNRN
NON-FINAL ACTION E-MAILED
Jun 19, 2012 GNRT
NON-FINAL ACTION WRITTEN
Jun 19, 2012 CNRT
ASSIGNED TO EXAMINER
Jun 12, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 8, 2012 NWOS
NEW APPLICATION ENTERED
Mar 5, 2012 NWAP